- cafead   Feb 23, 2023 at 10:22: AM
via A once highly touted gene therapy for sickle cell disease (SCD) has come to an end, at least internally, as Graphite Bio announced Thursday it is discontinuing the development of nulabeglogene autogedtemcel (nula-cel), its lead asset.
article source
article source